30 jul: UPDATE: GAIL India 1Q Net Profit Rises 15%, Tops Forecast
30 jul: 2nd UPDATE: Sweden GDP Growth Beats Forecasts, Boosts Krona
30-07-2012 14:45:00

GlaxoSmithKline PLC GSK announces initial tender offer results for HGS

Relateret indhold
16 jul - 
165 pct. i afkast i Bavarian Nordic på under ét år

TIDMGSK

RNS Number : 8116I

GlaxoSmithKline PLC

30 July 2012

Issued: Monday 30 July, 2012, London UK - LSE Announcement

GSK announces acquisition of 79% of Human Genome Sciences shares; commences subsequent offering period

GlaxoSmithKline plc (LSE: GSK) today announced the results of its initial tender offer for all outstanding shares of Human Genome Sciences (NASDAQ: HGSI) for US$14.25 per share in cash, valuing HGS at approximately US$3.6 billion on an equity basis, or approximately US$3 billion net of cash and debt.

The initial tender offer expired at midnight, New York City time, on 27 July 2012. The depositary for the tender offer has advised GSK that as of such time, approximately 158,607,627 shares had been validly tendered and not withdrawn, representing, together with shares beneficially owned by GSK, a total of approximately 79% of HGS' outstanding shares. An additional 9,155,762 shares were tendered subject to guaranteed delivery procedures, which represent approximately 4% of HGS' outstanding shares. All shares validly tendered and not withdrawn were accepted for payment.

GSK will provide a subsequent offering period for 4 business days commencing immediately for all remaining shares of HGS common stock to permit HGS stockholders who have not yet tendered their shares the opportunity to do so. This subsequent offering period will expire at 5:00 p.m., New York City time, on 2 August 2012. The same US$14.25 per share in cash offered during the initial offering period will be paid to holders of HGS common stock who tender their shares during the subsequent offering period. During the subsequent offering period, tendering stockholders will not have withdrawal rights.

Pursuant to the terms of the merger agreement, HGS granted to a wholly-owned subsidiary of GSK a top-up option to purchase from HGS the number of newly-issued shares of HGS common stock necessary for GSK to own at least 90% of the outstanding shares. GSK would be entitled to exercise and plans to exercise the top-up option if, following expiration of the subsequent offering period, GSK owns more than approximately 83% but less than 90% of the issued and outstanding shares.

Pursuant to the terms of the merger agreement, GSK is obligated to effectuate a merger of its wholly-owned subsidiary with and into HGS. At the effectiveness of the merger, each remaining share of HGS common stock not tendered (other than shares as to which holders properly exercise appraisal rights) is to be converted into the right to receive US$14.25 in cash, without interest and less any required withholding taxes. As a result of the merger, HGS common stock will cease to be traded on NASDAQ. If GSK owns at least 90% of the outstanding shares of HGS common stock following the subsequent offering period and, if necessary, the exercise of the top-up option, GSK expects to consummate a short-form merger with HGS.

Lazard and Morgan Stanley are acting as financial advisors to GSK, and Cleary Gottlieb Steen & Hamilton and Wachtell, Lipton, Rosen & Katz are providing legal advice to GSK.

V A Whyte

Company Secretary

30 July 2012

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com

GlaxoSmithKline Enquiries:

UK Media enquiries: David Mawdsley +44 (0) 20 8047 (London)

5502

Stephen Rea +44 (0) 20 8047 (London)

5502

Analyst/Investor enquiries: Sally Ferguson +44 (0) 20 8047 (London)

5543

Tom Curry + 1 215 751 5419 (Philadelphia)

Gary Davies + 44 (0) 20 8047 (London)

5503

James Dodwell + 44 (0) 20 8047 (London)

2406

Jeff McLaughlin + 1 215 751 7002 (Philadelphia)

Ziba Shamsi + 44 (0) 20 8047 (London)

3289

Sard Verbinnen & Co:

US Media enquiries: George Sard +1 212 687 8080 (New York)

Andrew Cole +1 212 687 8080 (New York)

Michael Henson +1 212 687 8080 (New York)

Cautionary statement regarding forward-looking statements

This communication contains forward-looking statements. GSK cautions readers that any forward-looking statements made by GSK, including those made in this communication, are subject to risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. Such forward-looking statements include, but are not limited to, statements about the benefits of a business combination transaction involving GSK and HGS, including future financial and operating results, GSK's plans, objectives, expectations (financial or otherwise) and intentions relating to the business combination and other statements that are not historical facts. Factors that may affect GSK's operations are described under 'Risk factors' in the 'Financial review & risk' section in GSK's Annual Report 2011 included as exhibit 15.2 to GSK's Annual Report on Form 20-F for 2011.

This announcement is for informational purposes only and does not constitute an offer to purchase or a solicitation of an offer to sell HGS common stock. The solicitation and offer to buy HGS common stock, commenced by GlaxoSmithKline plc through its wholly owned subsidiary, H. Acquisition Corp., have been made pursuant to an offer to purchase and related materials, filed on Schedule TO with the U.S. Securities and Exchange Commission (SEC), as amended and as will be further amended from time to time. In response to the offer, HGS has filed a solicitation/recommendation statement on Schedule 14D-9 with the SEC, as amended and as will be further amended from time to time. Investors and securityholders are urged to read these materials carefully since they contain important information, including the terms and conditions of the offer. Investors and security holders may obtain free copies of these materials and other documents filed by GSK and HGS with the SEC at the website maintained by the SEC as www.sec.gov. The offer to purchase and related materials may also be obtained for free by contacting the information agent for the tender offer, D.F. King & Co., Inc. at (212) 269-5550 or (800) 848-2998 (toll-free) or by email at HGStender@dfking.com.

Registered in England & Wales:

No. 3888792

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

This information is provided by RNS

The company news service from the London Stock Exchange

END

ACQEAFXEDSNAEFF

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

July 30, 2012 08:45 ET (12:45 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Aktier/middag: Investorerne slår koldt vand i blodet

23-04-2014 11:16:39
Efter en tirsdag hvor de danske og europæiske aktier blev sendt markant frem, er der mere ro på onsdag. Samlet bliver det til en lille nedgang for det toneangiv..

Aktier/tendens: Stigningerne vil løje af

23-04-2014 08:31:32
Efter en vild kursgalop tirsdag ventes det danske aktiemarked at slå over i skridt onsdag morgen.Futures på de europæiske aktiemarkeder ligger tæt på uændret, o..

OPTAKT Novozymes Q1 24/4: Vil starte året med høj vækst

22-04-2014 14:36:01
Novozymes er oppe mod nogle høje forventninger til væksten, når selskabet torsdag morgen offentliggør regnskab for årets første tre måneder. Ikke mindst salget ..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/tendens: Stigningerne vil løje af
2
Verdens største biotekselskab skuffer
3
Tirsdagens aktier: Genmab største vinder i massiv optur
4
Stort bud på Botox bekræftet
5
OPTAKT Novozymes Q1 24/4: Vil starte året med høj vækst

Relaterede aktiekurser

GlaxoSmithKline PLC 1.644,97 0,3% Stigning i aktiekurs
GlaxoSmithKline PLC 55,30 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Relaterede selskaber
Få adgang til information og anbefalinger af relaterede selskaber med PLUS pakken.

Du får adgang til 7 værdifulde investorværktøjer til investering.

Klik her og læs mere om PLUS pakken.
Euroinvestor i andre lande: Euroinvestor.com | Euroinvestor.se | Euroinvestor.no | Euroinvestor.fr | Forexinvestor.com| Wisselkoersen.nl | Valuta.se | Valutaveksel.no | Divisas.es | Valute.it
Copyright Euroinvestor A/S 2014  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
23. april 2014 12:21:42
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20140324.1 - EUROWEB3 - 2014-04-23 12:21:42 - 2014-04-23 12:21:42 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x